GLPG1690
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Lakefront Biotherapeutics NV
Overview
GLPG1690 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
GLPG1690 clinical trials
Explore related
Medical disclaimer. This page summarizes research about GLPG1690 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.